The lag time between onset of symptoms and diagnosis of rheumatoid arthritis.

OBJECTIVE Rheumatoid arthritis (RA) may be biologically reversible if treated in the first several months, yet it is unknown whether patients are diagnosed that early. We investigated the lag time between symptom onset and diagnosis of RA in a population with excellent access to rheumatology care. METHODS Using review of medical records, we evaluated all patients newly diagnosed as having RA from 1987 through 1990, at a health maintenance organization in central Massachusetts. Total lag time from symptom onset to first definite diagnosis was divided into medical encounter lag time (from symptom onset to first medical encounter) and diagnosis lag time (from first medical encounter to diagnosis). RESULTS The median total lag time was 36 weeks (range 4 weeks to > 10 years). The median medical encounter lag time was 4 weeks (not all patients included in the analysis). The median diagnosis lag time was 18 weeks. Diagnosis lag time was shorter for patients with progressive disease and positive rheumatoid factor on the initial test. Of 25 patients with symmetric arthritis and positive rheumatoid factor, only 5 (20%) were diagnosed within 2 months, and 10 (40%) were diagnosed more than 6 months after symptom onset. CONCLUSION RA diagnosis is usually delayed for several months after symptoms begin, in large part because of delay in diagnosis by the physician. Thus, the goal of initiating treatment extremely early may be unrealistic for most patients.

[1]  D. Cox,et al.  Analysis of Survival Data. , 1985 .

[2]  I. Kushner Does aggressive therapy of rheumatoid arthritis affect outcome? , 1989, The Journal of rheumatology.

[3]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[4]  U. Brodin,et al.  Auranofin improves outcome in early rheumatoid arthritis. Results from a 2-year, double blind placebo controlled study. , 1988, The Journal of rheumatology.

[5]  D. Felson,et al.  Incidence of rheumatoid arthritis in central Massachusetts. , 1993, Arthritis and rheumatism.

[6]  T. Pincus,et al.  Rheumatoid arthritis: disappointing long-term outcomes despite successful short-term clinical trials. , 1988, Journal of clinical epidemiology.

[7]  M. Weinblatt,et al.  Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. , 1992, Arthritis and rheumatism.

[8]  T. Pincus,et al.  Reassessment of twelve traditional paradigms concerning the diagnosis, prevalence, morbidity and mortality of rheumatoid arthritis. , 1989, Scandinavian journal of rheumatology. Supplement.

[9]  R M Kaplan,et al.  Prevalence of the use of unconventional remedies for arthritis in a metropolitan community. , 1989, Arthritis and rheumatism.

[10]  F. Epstein,et al.  Rheumatoid arthritis. Pathophysiology and implications for therapy. , 1990, The New England journal of medicine.

[11]  I. Kushner,et al.  Changing perspectives in the treatment of rheumatoid arthritis. , 1992, The Journal of rheumatology.

[12]  A. Linos,et al.  The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, prevalence, and mortality. , 1980, American journal of epidemiology.

[13]  J. Fries,et al.  The development of disability in rheumatoid arthritis. , 1986, Arthritis and rheumatism.

[14]  J J Anderson,et al.  The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials , 1993 .